Introduction {#s1}
============

The formation, processing, deposition and propagation of amyloid are at the center of a number of disease-associated and functional biological phenomena. While some amyloid aggregates are associated with devastating neurodegenerative diseases such as Alzheimer's, Parkinson's and prion diseases ([@bib12]; [@bib21]), other amyloid structures play many functional biological roles such as bacterial biofilm formation ([@bib24]; [@bib32]; [@bib6]), mammalian melanosome organization ([@bib3]) or epigenetic inheritance in yeast ([@bib44]). Some amyloid aggregates are recognized as prions because they form infectious particles, seeds that have the ability to be transmitted between cells, organs, individuals or even species ([@bib1]; [@bib31]; [@bib33]). Prions can subsequently propagate by converting their soluble and correctly folded protein counterparts into the amyloid fold ([@bib31]). However, this conversion process is not exclusive to prions as amyloid growth by elongation at fibril ends of preformed seeds recruits and converts soluble protein counterparts independently of the fibrillar seeds being transmissible prion particles or non-infections amyloid.

The molecular and cellular mechanisms underlying prion infectivity are not fully understood, but have been a key focus of research, particularly for the mammalian prion protein (PrP) which can be transmitted between hosts across different species ([@bib1]; [@bib46]). Indeed, there is compelling evidence that the transmission of PrP amyloid between cattle with Bovine Spongiform Encephalopathy and humans gave rise to a number of cases of so-called variant Creutzfeldt-Jakob disease ([@bib8]). Furthermore, recent studies have shown that several disease-associated amyloid aggregates such as α-synuclein (Parkinson's Disease), Tau (Alzheimer's disease and other tauopathies), amyloid-β (Alzheimer's disease) and huntingtin (Huntington's disease) are also capable of cross-cell transmission in a 'prion-like' manner (reviewed in \[[@bib2]\]). The possibility that such aggregates might also be infectious under some circumstances has also been suggested ([@bib17]). These new data highlight a gap in the knowledge of the factors that govern the infectious potential of amyloid particles in general. Why are some amyloid fibrils highly infectious prion particles while others are less infectious or even inert?

Amyloid fibrils are stable supramolecular structures characterized by the cross-beta molecular architecture supported by intermolecular hydrogen bonds parallel to the fibril axis ([@bib12]; [@bib21]). Their formation is usually preceded by protein misfolding events that result in the emergence of assembly-competent forms of amyloid-forming proteins ([Figure 1](#fig1){ref-type="fig"}). Amyloid formation then proceeds through nucleated polymerisation and fibril elongation with growth occurring by templated addition of monomeric protein to the fibril ends ([@bib35]; [@bib9]). The fragmentation of amyloid fibrils is an important secondary process that divides fibrils and increases the number of growth competent fibril ends, which consequently will accelerate amyloid growth ([@bib48]; [@bib20]). This secondary process can also increase the cytotoxic potential of amyloid particles ([@bib49]), as several studies have correlated smaller amyloid species with higher amyloid toxicity ([@bib41]). Despite its roles in disease-associated amyloid systems, fibril fragmentation is also crucial for ensuring the maintenance of functional amyloid such as yeast prions by producing sufficient number of growth competent amyloid particles to propagate the amyloid conformation and the prion phenotype ([@bib39]; [@bib45]).

![The prion lifecycle.\
The de novo formation of a prion involves reversible protein misfolding and consequential formation of amyloid conformers, which can assemble into small oligomeric species. Once this assembly reaches a critical size (i.e. the nucleus size), further polymerisation is favoured and fibrils grow by addition of protein monomer to their ends. This process can be accelerated by fibril fragmentation which increases the number of fibril ends to which monomer can be added. In the yeast *Saccharomyces cerevisiae* this is accomplished by the molecular chaperone Hsp104 and its co-chaperones and is essential to ensure a suitable number of prion particles (propagons) of the appropriate size is generated, ensuring their transmission during cell division. The process of fragmenting and transmitting prion particles is usually referred to as propagation.](elife-27109-fig1){#fig1}

The budding yeast *Saccharomyces cerevisiae* encodes a large number of functional prion-forming proteins, one of which is the translation termination factor Sup35 that, in its prion form, gives rise to the associated prion phenotype \[*PSI*^+^\] ([@bib44]; [@bib47]; [@bib28]). Translation termination occurs efficiently in prion-free cells (\[*psi*^-^\]), but is impaired when Sup35 switches to its prion conformation ([@bib47]; [@bib28]; [@bib10]; [@bib14]), making the Sup35 prion protein an epigenetic regulator of gene expression. In this system, the action of molecular chaperones, including Hsp104, catalyzes the fragmentation of the amyloid fibrils and ensures that sufficient amyloid particles (referred to as propagons) exist during cell division so that the prion phenotype is propagated to subsequent generations ([@bib7]; [@bib15]) ([Figure 1](#fig1){ref-type="fig"}). Crucially, fully synthetic prion particles formed in vitro from a recombinant form of Sup35 encompassing the first 253 residues of the protein (designated Sup35NM) are capable of being transfected into yeast cells and inducing the \[*PSI*^+^\] prion phenotype ([@bib19]; [@bib38]). This has provided us a highly tractable system that has allowed us to carry out a quantitative biophysical assessment of the factors that govern the infective potential of amyloid and prion particles.

Here, employing the Sup35NM/\[*PSI*^+^\] yeast prion system, we report a quantitative investigation into the infective potential of prion particles. We ask whether the dimensions and physical properties of prion particles can modulate their infective potential. This is achieved by quantifying the in vivo response of yeast cells to synthetic Sup35NM prion particles formed in vitro with recombinant Sup35NM and which have tailored length distributions by controlled fibril fragmentation. We use quantitative atomic force microscopy (AFM) and single-particle image analysis to characterize the morphology and suprastructure of the synthetic Sup35NM prion particles, and resolve their size distribution and particle concentration to a high quantitative detail. We then quantify the potential of these synthetic prion particles to transfect yeast cells and induce the heritable \[*PSI*^+^\] state in vivo. Our data show a striking relationship between the size distribution of prion particles and their ability to confer the prion phenotype associated with these particles. Detailed analysis of this relationship reveals that the ability to transfect and induce the \[*PSI*^+^\] phenotype is not identical for individual Sup35NM prion particles of different lengths, and has allowed us to estimate the particle size threshold for Sup35NM transfection of yeast cells using a simple modelling approach. Our results indicate that the physical dimensions of otherwise identical prion particles are key parameters that are sufficient to alter the infective potential of prion particles. These conclusions suggest possible routes to reduce prion and prion-like infectivity of amyloid by aggregate size modification approaches, for example by promoting the formation of large inert aggregates from transmissible particles or by increasing the stability of fibrils to reduce the creation of transmissible particles by fibril fragmentation, in strategies to combat the transmission of prions and amyloid particles.

Results {#s2}
=======

In vitro formation and AFM imaging of Sup35NM amyloid fibrils {#s2-1}
-------------------------------------------------------------

In order to analyze the effects of fibril dimensions on prion infectivity we first produced synthetic Sup35NM prion particles in vitro from recombinant monomeric Sup35NM, and generated fibril samples with a range of length distributions. The yeast prion protein Sup35 can be subdivided into three regions: N, M and C. The N (residues 1--123) and M region (124--253) are responsible for amyloid formation and prion maintenance, while the C terminal region of the protein (residues 254--685) is responsible for its translation termination function. When expressed in *E. coli*, the N + M regions (Sup35NM, residues 1--253) are sufficient to confer the \[*PSI*^+^\] phenotype when transfected into \[*psi*^-^\] yeast cells ([@bib19]; [@bib38]; [@bib37]). Recombinant Sup35NM protein monomers were therefore expressed in *E. coli* and purified under denaturing conditions as described in Materials and methods. Sup35NM polymerisation reactions were carried out in 20 mM sodium phosphate buffer, pH 7.4, 50 mM NaCl at a protein concentration of 10 μM to form Sup35NM amyloid fibril samples at a temperature of 30°C, which is the standard laboratory growth temperature for *S. cerevisiae*. Both de novo formation and polymerisation of Sup35NM under these conditions were monitored in parallel in reactions containing the fluorescent amyloid binding dye Thioflavin T ([Figure 2a](#fig2){ref-type="fig"}).

![In vitro polymerization and fragmentation of Sup35NM prion fibrils.\
(**a**) Sup35NM polymerization monitored using the amyloid-binding dye Thioflavin T. Five experimental replicates are plotted, with curves normalized to their upper baseline. (**b**) Representative atomic force microscopy images of Sup35NM amyloid fibrils before (0 s) and after sonication. Samples were diluted 1:300 prior to deposition on the mica surface except for the 0 s sample. Images of 10 μm x 10 μm in scan size are shown together with 4 x further magnified views. The scale bar represents the length of 2 μm in all images and arrows show examples of clusters of fibril particles.](elife-27109-fig2){#fig2}

Under the conditions employed, the Sup35NM polymerization reaction progress curves showed a sigmoidal shape expected for amyloid formation, with a lag phase of approximately 5 hr, followed by an exponential growth phase of approximately 5--10 hr in length. The reactions reached the upper plateau phase after approximately 20--30 hr. Analysis of the resulting amyloid fibrils using AFM imaging after the reactions reached the upper plateau ([Figure 2b](#fig2){ref-type="fig"}, *upper left image*) showed suprastructures consisting of large, intertwined networks of long fibrils. We next fragmented these fibrils by controlled sonication (see Materials and methods, [Figure 2b](#fig2){ref-type="fig"}). After 5 s of mechanical perturbation by sonication, a number of shorter and more disperse fibrils and small fibril clusters compared with non-fragmented initial samples were observed by AFM. An increasingly dispersed and non-clustered fibril population was observed with further sonication. A range of sonication durations were tested to generate a range of fibril sizes confirmed by AFM imaging ([Figure 2b](#fig2){ref-type="fig"}).

Characterization of Sup35NM prion particles {#s2-2}
-------------------------------------------

We next quantified the size distribution of the Sup35NM prion particles using a combination of sucrose density gradient analysis and semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) ([@bib23]). These biochemical methods have been previously used to distinguish prion aggregates in cell populations that have the prion phenotype versus those that do not, as well as to assess the occurrence of different prion conformational variants. Native sucrose density gradient analysis of Sup35NM amyloid fibrils fragmented to different extents by controlled sonication ([Figure 3a](#fig3){ref-type="fig"}) showed a clear shift in relative aggregate size after sonication. As seen in [Figure 3a](#fig3){ref-type="fig"}, fraction one containing monomeric Sup35NM was composed of less than 5% of total protein content in all samples, indicating that the polymerisation reaction had reached near-completion, and the controlled sonication had not caused increased free monomer concentration due to depolymerisation, as seen previously in other amyloid-forming systems ([@bib51]). The bulk of the fibril material shifted from the heavier to lighter fractions when sonication time was increased, indicating a reduction in the size distribution of the prion particles.

![Biochemical analysis of fragmented Sup35NM fibrils and their sizes.\
(**a**) Native sucrose density gradient analysis of sonicated Sup35NM fibrils. Each group of bars corresponds to one time-point, showing the percentage of total protein present in each of the nine gradient fractions. For each time point, three independent replicates were averaged. Error bars represent standard error of the mean. A representative Western blot for each of the time points is also shown. (**b**) SDD-AGE analysis, followed by immunoblotting, of the Sup35NM fibril samples. Samples sonicated for different periods of time are shown in each lane. A cell extract of \[*PSI*^+^\] cells is shown on the left most lane for comparison.](elife-27109-fig3){#fig3}

The differences in size distribution post-sonication were more difficult to detect when the fibril samples were characterized by SDD-AGE ([Figure 3b](#fig3){ref-type="fig"}). SDD-AGE analysis is performed under semi-denaturing conditions that do not disrupt the amyloid core of the fibril particles. Thus, the SDD-AGE data, which showed the position of the core Sup35NM aggregates as broad bands, did not reveal any change in electrophoretic mobility with increasing sonication duration after the first 15 s of sonication. This may reflect the breakup of the large fibril network from the first 15 s of sonication as seen in [Figure 2b](#fig2){ref-type="fig"}. However, the data demonstrate that SDD-AGE cannot distinguish further shortening of the amyloid particles or breakup of small fibril clusters ([Figures 2b](#fig2){ref-type="fig"} and [3a](#fig3){ref-type="fig"}) after the initial break-up of the fibril network. Importantly, the SDD-AGE analysis ([Figure 3b](#fig3){ref-type="fig"}) did indicate that the relative aggregate size in the \[*PSI*^+^\] cell extract used as a control only overlap with the in vitro generated sample that was sonicated for more than 15 s, indicating that the in vivo prion particles do not resemble the fibril network seen in the untreated synthetic sample ([Figure 2b](#fig2){ref-type="fig"}, 0 s). This result is corroborated by the fact that the in vitro generated sample that was not treated ([Figure 2b](#fig2){ref-type="fig"}, 0 s) cannot induce the \[*PSI*^+^\] phenotype, while the \[*PSI*^+^\] cell extract typically is able to induce 10--40% \[*PSI^+^*\] cells when transfected into \[*psi^-^*\] yeast cells under the standard conditions for transfection employed (Materials and methods, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Interestingly, the in vivo formed prion particles from the \[*PSI*^+^\] cell extract did overlap with the lower portions of the samples sonicated for longer periods than 15 s on SDD-AGE, suggesting that the prion species present in vivo may be represented by the lower molecular weight species in the in vitro assembled and sonicated fibril samples. The efficiency of a \[*PSI*^+^\] cell extract to induce \[*PSI^+^*\] cells when transfected into \[*psi^-^*\] yeast cells is highly variable due to many factors such as differences in protein expression levels of Sup35, the prion strain variant present as well as the variable repertoire of chaperones and other cellular factors that associate with the fibrils. Therefore, to isolate the effect of particle dimensions on their ability to transfect cells, we next analyzed in detail the dimensions of the in vitro assembled and sonicated fibril samples and assessed their ability to induce the \[*PSI^+^*\] state in \[*psi^-^*\] cells.

Size distribution and particle concentration quantification of Sup35NM prion samples {#s2-3}
------------------------------------------------------------------------------------

To resolve the detailed length distribution and the size change of the amyloid particles in our samples in absolute length units, we next imaged and measured the length of individual particles using AFM and carried out length distribution analysis ([@bib51]) on the Sup35NM fibril samples. This analysis was then used to estimate particle number concentration, particle widths (particle heights in AFM image data) and particle lengths for each individual synthetic prion sample. A total of 72 images were collected and analyzed for 26 samples, with at least two images and a minimum of 500 particles per sample analyzed to ensure sufficient numbers of fibril particles were taken into account (see [Table 1](#table1){ref-type="table"}).
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###### Quantitative analysis of Sup35NM amyloid fibril samples.

Sample and image analysis statistics for characterized Sup35NM amyloid fibril samples.

  Sample   Fragmentation   AFM image analysis   Prion transfection                        
  -------- --------------- -------------------- -------------------- ------ ----- ------- ------
  1        15              5                    189.7                1805   7.0   27965   12.3
  2        30              5                    121.9                6110   6.1   64381   25.0
  3        60              2                    112.3                5500   6.2   63114   29.4
  4        120             2                    111.7                5814   6.9   79594   35.0
  5        240             2                    88.4                 7478   7.2   88175   36.7
  6        480             2                    74.5                 8564   7.8   91816   59.5
  7        960             2                    77.2                 8604   8.1   92713   68.9
  8        15              4                    231.1                1560   6.7   24809   12.6
  9        30              4                    141.8                2699   6.5   33303   17.3
  10       60              2                    184.8                2003   7.2   31931   9.2
  11       120             2                    125.9                4562   7.1   63937   27.7
  12       240             2                    84.3                 4169   7.0   48486   24.7
  13       480             2                    68.9                 5662   7.5   57393   42.0
  14       960             2                    70.9                 5717   7.8   62894   51.2
  15       30              4                    142.3                675    7.1   9353    6.7
  16       60              3                    131.8                1937   6.8   24348   13.1
  17       120             2                    161.0                1909   7.1   27013   23.5
  18       240             2                    87.0                 4269   7.0   49000   21.9
  19       480             3                    88.8                 2938   7.0   33342   21.6
  20       960             2                    85.7                 4687   7.4   56457   35.6
  21       30              6                    160.5                3306   6.9   47476   \-
  22       60              4                    150.0                3523   7.5   47590   \-
  23       120             2                    184.2                2198   7.0   32565   \-
  24       240             2                    133.3                1803   7.5   24158   \-
  25       480             2                    150.6                1455   7.3   21163   \-
  26       960             2                    64.3                 8000   7.3   77914   \-

In general, increased time of controlled mechanical perturbation by sonication resulted in a decrease of the mean particle size as previously shown ([@bib51]; [@bib50]), with longer sonication times producing smaller mean fibril lengths ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). This can also be seen in the sample particle length distributions ([Figure 4a](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), which show the presence of an increasing number of smaller particles when samples were sonicated for longer periods. As seen in [Figure 4a](#fig4){ref-type="fig"}, the average length of the Sup35NM prion particles reduced from over 210 ± 21 nm to 75 ± 5 nm over the course of 16 min (960 s) of controlled sonication. We also analyzed the height across all particles, which is indicative of the particle widths ([Figure 4c](#fig4){ref-type="fig"}). This showed that the average particle width remained largely unchanged when sonication time was increased, with the mean height observed at 7.1 ± 0.5 nm. The average dimensions of the fibril particles after extended periods of mechanical perturbation by sonication is also comparable to that expected for protein filaments with tensile strength of 0.2 GPa undergoing sonication-induced scission ([@bib16]). These observations are consistent with the fact that the controlled mechanical perturbation resulted in a reduction in particle length, but did not otherwise alter the individual fibril assemblies.

![Single-particle analysis of Sup35NM fibril length distribution after controlled sonication.\
(**a**) Particle size distributions for seven representative Sup35NM samples sonicated for different times. The occurrence of different particle sizes was normalized against the total number of particles traced for each individual sample and plotted against particle length (blue lines). Sonication time and the number of fibrils analyzed for each sample are displayed in each plot. (**b**) Relationship between mean particle length and sonication time. Each data point represents the mean of all individual samples analyzed for a given time point. Error bars represent the standard error of the mean. (**c**) Relationship between mean particle height, representing the width of the fibril particles, and sonication time. Each data point represents the mean of all individual samples analyzed for a given time point. Error bars represent the standard error of the mean. The mean height of all values is represented by the solid red line, with its standard error represented by the dotted red lines.](elife-27109-fig4){#fig4}

Taken together with the biochemical characterizations of the fibril samples, our results indicate that non-sonicated in vitro generated Sup35NM amyloid particles form a suprastructure consisting of large fibril networks that do not reflect the size and the suprastructure of prion particles present in vivo in \[*PSI*^+^\] cells. The controlled sonication alters this suprastructure by initially dispersing the fibril network into smaller clustered aggregates, and subsequently produces dispersed fibril particles with size distributions overlapping with that of particles present in vivo in \[*PSI*^+^\] cells. Further sonication then proceeds to further reduce the length distribution of the resulting dispersed fibril particles, but the mechanical perturbation employed did not otherwise change the width of these particles.

Influence of fibril particle concentration and size on prion transfection efficiency {#s2-4}
------------------------------------------------------------------------------------

Lastly, we measured the ability of the synthetic fibril samples to induce the \[*PSI*^+^\] phenotype in vivo in yeast cells. *S. cerevisiae (*74D-694 \[*psi*^-^\]) cells were transfected by 20 different fibril samples that had their size distributions characterized in detail by AFM image analysis as described above ([Table 1](#table1){ref-type="table"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The fibril samples were added to the yeast transfection reaction at the same time they were deposited on mica for the AFM analysis to eliminate the impact of sample-to-sample particle size variations (as shown in [Figure 4](#fig4){ref-type="fig"}) on \[*PSI*^+^\] transfection efficiency determinations. [Figure 5a and b](#fig5){ref-type="fig"} show the relationship between the average particle lengths of the samples and their efficiencies in inducing the \[*PSI*^+^\] phenotype. Under the conditions employed, fibril samples with average particle length ranging from 231 nm to 69 nm resulted in \[*PSI*^+^\] transfection efficiencies ranging between 7% and 69% ([Table 1](#table1){ref-type="table"}).

![Prion infective potential depends on particle size, concentration and activity.\
(**a**) Analysis of prion transfection efficiency. AFM images of representative Sup35NM fibrils samples sonicated for 15 s (upper) and 960 s (lower) are shown together with plates containing yeast colonies grown from protoplasts transfected with the Sup35NM fibrils samples, indicating the sample's ability to infect yeast cells and to induce \[*PSI^+^*\] phenotype in vivo. Scale bars indicate the length of 1 μm. Individual yeast colonies were scored as \[*PSI^+^*\] (white dots) or \[*psi^-^*\] (red dots) based on their colour in ¼ YEPD and curability in ¼ YEPD supplemented with 3 mM GdnHCl ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Colonies that showed poor growth or unrecognisable colour differentiation were omitted (black dots). On each plate, control \[*PSI^+^*\] (white) and \[psi^-^\] (red) colonies are present at the upper right corners for comparison. See [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} for the full data set. (**b**) Dependency of prion transfection efficiency on particle size. Mean fibril length for each of the 20 samples analysed is plotted against the percentage of *S. cerevisiae* \[*PSI^+^*\] colonies obtained after prion transfection. Inset show dependency of prion transfection efficiency on particle concentration calculated from the length distribution of the samples. The dashed red line denotes best fit linear model with the slope of 9.3·10^8^ M^−1^ and the intercept of −11.3% with 95% confidence interval for the intercept between −26.0% to −0.7%, demonstrating that this linear model is not the correct model to describe the transfection efficiency as function of particle length or particle concentration. (**c**) Transfection activity of the Sup35NM fibrils samples estimated as the percentage of fibril particles less than 200 nm long show against the average particle length of each fibril sample. Insets show representative particle length distributions of the fibril samples shown in (**a**) sonicated for 15 s (blue distribution/arrow) and 960 s (red distribution/arrow), with shaded areas denoting particles larger than 200 nm long. (**d**) Dependency of prion infective potential on active particle concentration consisting of fibril particles less than 200 nm long. The red line denotes best-fit linear model with the slope of 7.6·10^8^ M^−1^.](elife-27109-fig5){#fig5}

Knowing the length distribution of the fibril samples allows the calculation of their fibril particle concentrations ([@bib51]). Comparing \[*PSI*^+^\] transfection efficiencies with their corresponding fibril particle concentrations ([Figure 5b](#fig5){ref-type="fig"}) revealed a striking correlation, indicating that the ability of Sup35NM fibril particles to induce the \[*PSI*^+^\] prion phenotype depends on the number of particles present. Interestingly however, as seen in [Figure 5b](#fig5){ref-type="fig"}, this correlation deviated from the expected linear behavior where 0% \[*PSI*^+^\] prion phenotype would result from a particle concentration of 0 M (the x-intercept of the dashed line is 12.2 nM in [Figure 5b](#fig5){ref-type="fig"} inset), suggesting that fibril particles are not equally capable at inducing the \[*PSI*^+^\] prion phenotype. This is consistent with the fact that fibril samples that were not sonicated ([Figure 2b](#fig2){ref-type="fig"}, *upper left image*) cannot induce the \[*PSI*^+^\] prion phenotype, since the particle concentration for the non-sonicated sample still must be greater than 0 M. Therefore, our analysis suggests that longer particles are less able to induce the \[*PSI*^+^\] prion phenotype compared to identical numbers of their shorter counterparts.

There are two possibilities that can explain the observed higher infective potential of short particles compared with the same number of their longer counterparts; (a) the particles of different lengths are not equal in recruiting soluble intracellular Sup35 and seeding the conversion and growth of new amyloid, or (b) the particles are not equally capable of crossing the cell membrane and access the cellular environment to elicit the \[*PSI*^+^\] phenotype. To test whether the observed differences were due to a poor ability of larger particles to seed amyloid growth, we performed seeded amyloid growth assays monitored by Thioflavin T ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) where 10 uM fresh Sup35NM monomers were seeded by 1% of the fibril samples sonicated to different extents. The seeding potential of the fibril particles was determined by measuring the initial slope of the seeded growth curves and the resulting slope value compared with each sample's known particle concentration. All samples analyzed were capable of seeding the polymerisation of monomeric Sup35NM, albeit to different extents, with those sonicated for longer periods doing so with greater efficiency ([Figure 5---figure supplement 2a](#fig5s2){ref-type="fig"}) as expected for amyloid growth by monomer addition at fibril ends. As seen in [Figure 5---figure supplement 2b](#fig5s2){ref-type="fig"} (blue data points), and in contrast with the \[*PSI*^+^\] transfection efficiencies, the seeding ability of the different fibril samples depended solely on the number of fibril particles, with the initial slope of seeded growth curves showing a linear correlation with particle concentration that was not significantly different to the expected trend where 0 M particles should result in 0 hr^−1^ initial slope. To further confirm this result, we made a prediction that seeding with the same particle concentrations using samples of different length distributions should result in the same seeding efficiency. Here, the average length of particles in sample sonicated for 60 s is 145 nm, about twice as long as average length of particles in sample sonicated for 960 s (average length of 75 nm). Therefore, the particle concentration of the sample sonicated for 60 s is roughly half that of the sample sonicated for 960 s. Consequently, an assembly reaction seeded by 2% of the sample sonicated for 60 s is predicted to be as efficient as the reaction seeded by 1% of sample sonicated for 960 s. We carried out experiments to test this prediction by seeding new reactions with 1% as well as 2% of an independent fibril sample sonicated for 60 s ([Figure 5---figure supplement 2b](#fig5s2){ref-type="fig"}, yellow data points). As seen in [Figure 5---figure supplement 2b](#fig5s2){ref-type="fig"}, a reaction seeded by 2% of the independent sample sonicated for 60 s (upper right yellow cross) reproduced the same efficiency as a reaction seeded with 1% sample sonicated for 960 s (upper right blue cross) that had a comparable particle concentration. These results rule out that the particles are sufficiently unequal in seeding the conversion and growth of new amyloid, and therefore suggest that particles are not equally capable of crossing the cell membrane to access the intracellular environment and elicit the \[*PSI*^+^\] phenotype.

Next, we investigated how particle size might modulate the relationship between particle concentration and \[*PSI*^+^\] transfection efficiencies. Were transfection efficiency dependent solely on particle concentration, it would be expected for a transfection efficiency of 0% to occur at 0 M particle concentration and increase linearly from that point. This was not the case for our data (dashed line in [Figure 5b](#fig5){ref-type="fig"}). Hence, we propose the introduction of a transfection activity coefficient, *γ~transf~*, that is capable of representing the fibril particles' infective potential. We then define an active particle concentration $c_{p,transf}\left( l \right)$ depending on the particle length $l$ so that:$$c_{p,transf}\left( l \right) = \ \gamma_{transf}\left( l \right) \cdot c_{p}\left( l \right)$$

where *c~p~* is the particle concentration and $l$ is particle length. We then assume the simplest possible model where there is a particle size 'cut-off' $l^{*}$, and particles longer than this cut off will not be able to transfect yeast cells and induce the \[*PSI*^+^\] prion phenotype (i.e. *γ~transf~* for an individual particle is 0 when its length is longer than $l^{*}$ and one if its length is shorter or equal than $l^{*}$). This can be written as the following relationships:$$\gamma_{transf}\left( {l,l^{\ast}} \right) = \left\{ \begin{matrix}
{1,} & {l \leq l^{\ast}} \\
{0,} & {l > l^{\ast}} \\
\end{matrix} \right.$$

The total transfection active particle concentration *c~p,transf~* is then the sum of all active particles:$$c_{p,transf} = \sum\limits_{l}c_{p,transf}\left( l \right) = \sum\limits_{l}\gamma_{transf}\left( {l,\ l^{\ast}} \right) \cdot c_{p}\left( l \right)$$

To establish the particle size 'cut-off' $l^{*}$ that is most consistent with our data, we systematically tested possible $l^{*}$ values, and found that when $l^{*}$ is 200 nm ([Figure 5c](#fig5){ref-type="fig"}) then the calculated activity of the fibril samples in terms of their active particle concentration satisfies the criteria that it correlates with the transfection efficiency with the anticipated transfection efficiency of 0% occurring at 0 M particle concentration ([Figure 5d](#fig5){ref-type="fig"}). To test the predictive abilities of this model, we next calculated the average active particle concentration of the whole sample sonicated for 15 s and 960 s, respectively. For the sample sonicated for 15 s, the particle concentration was estimated to be 22 nM based on their average length of 210 nm, and the average transfection activity coefficient of this sample was 0.55 ([Figure 5c](#fig5){ref-type="fig"}). According to our model with $l^{*}$ = 200 nm, this gives for transfection an active particle concentration of 12.1 nM. For the sample sonicated for 960 s, the particle concentration was estimated to be 61 nM from average length of 75 nm, and the average transfection activity coefficient of this sample was 0.98 ([Figure 5c](#fig5){ref-type="fig"}), giving an active particle concentration of 59.8 nM, roughly five times higher than the sample sonicated for 15 s. Consequently, our model predicts that a five times dilution of a sample sonicated for 960 s will result in the same transfection efficiency as a sample sonicated for 15 s. On the other hand, if our size cut-off model is incorrect and all effect on transfection efficiency is based purely on the total particle concentration then we expect five times dilution of a sample sonicated for 960 s will give roughly half the transfection efficiency compared to that of a sample sonicated for 15 s. We tested this prediction experimentally by measuring the ability of independent samples sonicated for 15 s and 960 s to induce the \[*PSI*^+^\] phenotype ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). This experiment confirmed that the transfection efficiencies of the samples sonicated for 15 s is indistinguishable compared to five times diluted samples sonicated for 960 s, which was predicted to have equal active concentration of prion particles. Thus, these results are consistent with the predictions of our size cut-off model that particles longer than 200 nm in length are likely to be incapable of entering the cells and induce the \[*PSI*^+^\] prion phenotype. In reality, the efficiency with which fibril particles enter the cells and propagates the prion phenotype may be a continuous and non-linear function of their dimensions. However, our simple model, with a size cut-off estimate that particles of 200 nm or less in length are capable of entering the cells and conferring the \[*PSI*^+^\] prion phenotype, is fully consistent with the data. Assuming the fibril volume is estimated by cylinders of 7.1 nm diameter based on the AFM height data ([Figure 4c](#fig4){ref-type="fig"}) and a fibril density comparable to that of folded proteins at 1.4 g/cm^3^ ([@bib13]), then the molecular weight of a 200 nm particle is approximately 7 MDa. The estimated particle length cutoff is also corroborated by the AFM images of the sample series, showing fibril clusters persist in the same size range as our cutoff estimate or larger (e.g. arrows in 15, 30 and 60 s images in [Figure 2b](#fig2){ref-type="fig"}). In summary, these results demonstrate that the infective potential of the Sup35NM prion samples depends on effective particle concentrations that only take into consideration a subpopulation consisting of prion particles of optimal dimensions for transfection.

Discussion {#s3}
==========

Infectivity and cell-to-cell propagation are two of the main criteria that set prions apart from other amyloid aggregates ([@bib43]). Amyloid fibril fragmentation is a crucial process that potentiates propagation by increasing the number of transmissible, seeding competent particles and as we demonstrate here, also by producing particles that are of an 'ideal size' for transmission. A growing number of disease-associated amyloid forming proteins appear to possess prion-like properties in that these amyloid particles can be transmitted to nearby cells to effectively propagate the amyloid-associated phenotype to previously healthy cells ([@bib2]). These findings blur the line between transmissible and non-transmissible amyloid, suggesting that the infectious potential of amyloid is a complex biological property that is better described by a sliding scale rather than the binary prion/non-prion view.

In the case of the prion-like amyloid proteins such as Aβ ([@bib26]), α-synuclein ([@bib25]), tau ([@bib34]), and huntingtin ([@bib29]), transmissibility has been linked to a number of active protein import and export mechanisms ([@bib2]). However, the possibility that cell-to-cell transmission occurs by diffusion across the cellular membrane cannot be discounted. Studies of the mammalian prion protein PrP have shown that small prion particles consisting of 14--28 PrP monomers are more infections than their larger counterparts ([@bib36]), indicating that particle size plays an important role in mammalian prion infectivity. Furthermore, it has also been shown that exogenous, recombinant Sup35NM amyloid can be used to infect and confer a prion phenotype to mammalian N2a cells expressing a soluble, cytosolic form of Sup35NM ([@bib22]). Taken together, these data indicate that transmissibility might be a general property of all amyloid aggregates, which will invariably occur given the right physical properties and conditions. This makes it crucial that we fully understand how the mesoscopic and suprastructural properties of amyloid particles influences their transmissibility as well as identifying how passive and/or active protein transport mechanisms could contribute to this phenomenon.

Once formed in a cell, the continued and efficient propagation of a given yeast prion occurs as cells divide, fuse during mating ([@bib43]) or give rise to the products of meiosis (sporulation), and is greatly facilitated by the cytoplasmic location of the transmissible forms of the prion. This propagation is thought to occur passively by cytoplasmic transfer, as no active mechanisms for transmission of prion particles have yet been identified ([@bib5]) although the possibility that extracellular vesicles may facilitate the vertical and horizontal transmission of yeast prions has been raised ([@bib18]). Infection with amyloid particles can also be achieved experimentally by transfecting yeast protoplasts that are largely devoid of the normally protective and robust cell wall ([@bib19]; [@bib38]).

In this study, we have taken advantage of the fact that we could quantitatively determine the lengths of single prion particles using AFM image analysis and calculate particle concentrations. By then coupling this with yeast transfection we have been able to determine how these properties affected the efficiency with which they crossed the yeast cell membrane into the cytoplasm and induce the \[*PSI^+^*\] prion phenotype in vivo. Use of this now well-established yeast prion infection model has allowed us to systematically investigate how length distribution and particle concentration affect the activity of amyloid particles to cross cellular membranes and infect yeast cells. The key conclusion that has emerged from our analysis is that infectivity is only proportional to particle concentration when the particles are of favorable size and free from forming aggregate suprastructures ([Figure 6](#fig6){ref-type="fig"}).

![The physical dimensions of prion particles modulate their suprastructure and their infective potential.\
The length of individual Sup35NM amyloid fibrils modulate whether they are active prion particles that can infect cells and induce the \[*PSI^+^*\] prion phenotype or form inactive suprastructures in the form of fibril clusters and networks. Thus, the infective potential of prion samples may be represented in terms of an average per particle activity (top sliding bar). Here, the active Sup35NM yeast prion population is represented by an active population of particles less than \~200 nm long, which are able to cross the membranes of yeast protoplasts and enter the prion lifecycle in the cells. Particle sizes larger than 200 nm are non-infectious, most likely because they cannot cross the cell membrane, but this may also be due to the possibilities that they cannot interact with or are actively sequestered away from the propagation machinery due to their aggregate size.](elife-27109-fig6){#fig6}

Using a simple model to estimate the infectious activity of Sup35NM prion samples based on their length distribution, we show that the particle concentration versus transfection activity correlation only applies when taking into account an active particle concentration based on prion particles up to a certain length. This has led us to estimate the size cut-off for infectivity of Sup35NM particles at approximately 200 nm. Above 200 nm, the individual Sup35NM prion particles are likely to interact and form higher-order aggregate suprastructures ([Figure 2b](#fig2){ref-type="fig"}, 0 s, and arrows in 15--60 s), which bear similarity to what has been described as flocculation or gelation ([@bib4]). The fibrils in the aggregated suprastructures are relatively inert compared with their shorter, less aggregated counterparts, and they are non-infectious. Below this size threshold, infectivity is largely dependent on particle concentration. Thus, the infectious potential of prion samples, in terms of average transfection activity per particle, is likely a non-linear function (e.g. [Figure 5c](#fig5){ref-type="fig"} for Sup35NM particles analyzed here) that depends on the size distribution of the particles ([Figure 6](#fig6){ref-type="fig"}). The activity of the particles as function of their size will subsequently depend on particle-particle interactions coupled with the mesoscopic properties of the aggregates, and may be further dependent on the particles' interactions with other cellar components inside cells, on their interactions with membranes and other surfaces, and on their diffusion properties. In terms of surface interactions, the same active surface that promotes secondary nucleation may also give rise to particle-particle interactions or interactions with membranes and other surfaces ([@bib4]), thus modulating the suprastructure and infective potential of the particles. In the case of diffusion, the effect of particle size on translational and rotational diffusion coefficients of rod-like particles are proportional to 1/length and 1/length^3^, respectively ([@bib27]). Therefore, the length dependence of diffusion is considerably larger for small particles roughly below \~50 nm in length compared with their longer counterparts ([@bib27]), suggesting that diffusion may play additional role for the increased activity of small mobile particles if they are much smaller than \~50 nm. In any case, resolving the activity function ([Equation 2](#equ2){ref-type="disp-formula"}) for other prions and prion-like amyloid systems and understanding the molecular origins of the constitutive components of this function in order to understand the size--suprastructure--activity relationships of the amyloid and prion particles will undoubtedly reveal why some amyloid aggregates are inert while others are cytotoxic and/or infectious.

Successful prion infection depends not only on a particle's ability to cross the cellular membrane but also on its interactions with intracellular factors such as chaperones, co-chaperones and the proteostasis machinery in general. These downstream interactions are eventually translated into successful propagation of prions in yeast and in pathogenic prion systems. While our data suggest that the size threshold and clustering and fibril network formation result in a reduced ability of particles to cross the cell membrane, further direct observations of prion particles entering the cells and interacting with cellular machineries inside the cell volume will shed light on the role of intracellular processes such as chaperone interactions and cellular sequestration or degradation, which may also influence the effect of particle shape, size and suprastructure on prion propagation. Much like the data we here show for prion infectivity, intracellular prion propagation in yeast has previously also been shown to be a 'size-based' process ([@bib11]), which further emphasizes existence of physical size barriers in amyloid transmission.

In conclusion, our findings show that the physical dimensions are an important parameter to take into account when assessing the infective potential of amyloid particles. Since large amyloid fibril networks are likely to be relatively inert suprastructures compared with small diffusible fibril particles, calculating size thresholds for effective transmission activity should be of particular importance when examining the infectious potential of prion-like amyloid structures as well as large structures such as amyloid plaques, which are thought to be largely inert ([@bib41]). This leads us to suggest that strategies to promote pre-formed amyloid assembly into large, non-transmissible amyloid structures might be able to control their prion-like transmission, and subsequently delay amyloid disease progression. Further analysis of the size and infective potential of the large amyloid suprastructures as well as smaller amyloid polymers or particles, which might arise through mechanical or enzymatic action ([@bib30]), will also be crucial in deciphering their fundamental biological and cellular activities. A molecular understanding of the amyloid fibrils' stability towards fragmentation, as well as how fibril fragmentation is catalyzed in the cell by chaperones such as Hsp104, Hsp70 and Hsp40, will lead us to a better understanding, and suggest diagnostics and therapeutics to combat amyloid transmission, amyloid disease progression and prion infectivity.

Materials and methods {#s4}
=====================

Protein expression and purification {#s4-1}
-----------------------------------

The region of the *SUP35* gene encoding the NM region of the yeast Sup35 protein (residues 1--253) was amplified from plasmid pUKC1620 by PCR and cloned into pET15b as a *Bam*HI-*Nde*I fragment. This generated an N-terminal His~6~-tag fusion protein. The resulting plasmid (pET15b-His~6~-NM) was then transformed into the *E. coli* strain BL21 DE3 (*F-- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 \[lacI lacUV5-T7 gene 1 ind1 sam7 nin5\]*). For protein expression, BL21 DE3 was grown overnight in 50 ml LB supplemented with 0.1 mg/ml ampicillin and then transferred to 1 L cultures of the same medium. On reaching an OD~600~ of approximately 0.5, expression was induced with 1 mM IPTG for 4 hr. Cells were harvested at 6000 rpm and the cell pellets washed once in buffer A1 (20 mM Tris-HCl pH 8.0, 1 M NaCl, 20 mM Imidazole). Cells were pelleted and kept at −80°C for later use. For the affinity purification step, buffer A2 (20 mM Tris-HCl pH 8.0, 1 M NaCl, 20 mM Imidazole, 6 M GdnHCl) was added to the frozen cell pellets at a 5:1 (v/v) ratio, followed by sonication at an amplitude of 22 microns until the cell pellet was completely disrupted. This solution was then subject to centrifugation at 13000 rpm for 30 min and the resulting supernatant collected. 1 ml of Chelating Sepharose Fast Flow (GE Healthcare) was added to a small plastic column and prepared for affinity purification by sequential washing with one column volume (CV) of water, 0.2 M NiCl~2~, buffer A1 and buffer A2. The equilibrated resin was then resuspended in buffer A2 and added to the previously collected supernatant. This mixture was then incubated for 1 hr at room temperature with agitation to improve protein binding to the affinity resin. Centrifugation at 5000 rpm was subsequently used to collect the resin, which was then washed in 5 ml buffer A2 and resuspended in buffer A2 and transferred back to the column. After one wash with 1 CV buffer A2, elution was achieved by addition of 4 ml buffer A3 (20 mM Tris-HCl pH 8.0, 1 M NaCl, 0.5 M Imidazole, 6 M GdnHCl). The resulting eluate was immediately used in size-exclusion purification, which was run using a HiLoad 16/600 Superdex 200 pg (GE Healthcare) column in an ÄKTA Prime Plus chromatography system (GE Healthcare). The eluate was injected into the size-exclusion column previously equilibrated with 1 CV water followed by 1 CV buffer S1 (20 mM Tris-HCl pH 8.0, 0.5 M NaCl) and 1 CV buffer S2 (20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 6 M GdnHCl). The relevant Sup35NM protein fractions were collected according to the A~280~ displayed throughout the run, diluted to 20 μM in buffer S2 and immediately used in fibril-forming reactions.

Sup35NM fibril formation {#s4-2}
------------------------

For fibril formation, 2.5 ml of 20 μM purified Sup35NM were buffer exchanged into Fibril Forming Buffer (FFB - 20 mM Na~2~PO~4~ pH 7.4, 50 mM NaCl) using a PD-10 column (GE Healthcare) as per manufacturer's instructions. Protein concentration was measured using A~280~ and then adjusted to 10 μM using FFB. Protein was aliquoted into Protein LoBind tubes (Eppendorf) and polymerized at 30°C (quiescent) for at least 48 hr. For monitoring polymerisation, 100 μl samples of protein were aliquoted into black puregrade 96-well plates (BRAND) and Thioflavin T was added to a final concentration of 10 μM. The plate was sealed with Starseal Advanced Polyolefin Film (Starlab) and kinetics were monitored in a FLUOstar OMEGA plate reader (BMG Labtech) at 30°C.

Sup35NM fibril fragmentation {#s4-3}
----------------------------

Sup35 fibril samples were concentrated by centrifugation at room temperature (13000 rpm, 40 min) and resuspended in 1:10th of the volume of FFB, unless stated otherwise. Fibril fragmentation was achieved by sonication over different periods using a probe sonicator (Qsonica Q125) at 20% amplitude in consecutive 5 s on/off cycles on ice cooled water-bath.

Sucrose density gradient analysis {#s4-4}
---------------------------------

15% to 60% sucrose gradients were prepared in FFB. Fibril samples used in sucrose gradients were concentrated by centrifugation at room temperature (13000 rpm, 40 min) and then resuspended in half the volume of FFB before sonication, which was performed as described above. 100 μl of samples sonicated for different amounts of time were pipetted onto the top of a sucrose gradient and centrifuged at 31,000 rpm, 4°C, for 3 hr. Gradients were sampled while on ice by pipetting 221 μl fractions from the top of the gradient into pre-chilled tubes which were snap-frozen in liquid nitrogen and stored at −80°C for subsequent western blot analysis. Each gradient produced nine fractions. 10 μl of each fraction was analysed on a 4--20% polyacrylamide Tris-Glycine gradient gel (Invitrogen, Waltham, MA) run at 125 V. Proteins were transferred onto a PVDF membrane by semi-dry blotting (10 V, 45 min) and membranes were probed with anti-Sup35 (MT50) polyclonal antibody. Anti-rabbit HRP-conjugated antibody was used as a secondary antibody in standard ECL analysis. For densitometry, the image analysis software ImageJ (version 1.42, <http://rsbweb.nih.gov/ij/>, RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)) was used. Relative intensity of each band was calculated by dividing the given intensity value for each band by the total intensity value for all bands in that sample.

Semi-denaturing agarose gel electrophoresis (SDD-AGE) {#s4-5}
-----------------------------------------------------

SDD-AGE analysis was performed as previously described ([@bib23]) with the following modifications. Sonicated fibrils were obtained as described above and loaded in a 1.5% agarose gel prepared in buffer G (20 mM Tris, 200 mM glycine) and ran on Laemmli buffer (20 mM Tris, 200 mM glycine, 0.1% SDS). Proteins were transferred using semi-dry blotting and transfer buffer T (20 mM Tris, 200 mM Glycine, 0.1% SDS, 15% (v/v) methanol) onto a PVDF membrane for 90 min at 10 V. MT50 anti-Sup35 primary antibody was used in western blot analysis as described above. Cell extracts used in SDD-AGE were prepared by first harvesting yeast cells (≈2·10^7^ cells) and resuspending the pellet in 100 μl PEB buffer (25 mM Tris-HCl pH 7.5, 50 mM KCl, 10 mM MgCl2, 1 mM EDTA and EDTA-free Protease Inhibitor Cocktail \[Roche\]). Approximately one pellet volume of small glass beads was added to the resuspended cells and lysis performed by vortexing at 4°C. Lysate was then cleared by centrifugation (8000 rpm, 10 min, 4°C) and total protein concentration in the collected clear lysate was measured by A280. Approximately 100 μg total protein were loaded per lane.

Prion transfection {#s4-6}
------------------

For prion transfection with synthetic Sup35NM amyloid fibrils, a \[*psi*^-^\] derivative of the yeast strain 74D-694 (*MATα ade1-14 trp1-289 his3Δ−200 ura3-52 leu2-3,112*) was used with an adaptation of a previously published amyloid fibril transformation protocol ([@bib40]). Cells were inoculated in 5 ml YEPD and grown overnight at 30°C with agitation. They were then diluted into fresh YEPD and allowed to grow to an OD~600~ of 0.5. Cells were than washed and resuspended in 12 ml ST buffer (1 M sorbitol, 10 mM Tris-HCl pH 7.5). Spheroplasts were prepared by addition of 600 U of lyticase (Sigma L4025) and 10 mM DTT and incubated at 30°C with agitation for 45 min. Spheroplasts were then harvested by centrifugation (400 x*g*, 5 min), successively washed with 1.2M sorbitol and STC buffer (1.2 M Sorbitol, 10 mM Tris-HCl pH 7.5, 10 mM CaCl~2~) and then resuspended in 1 ml STC buffer. Each transformation reaction consisted of 100 μl spheroplast suspension, 2 μl (approximately 1 μg) of plasmid DNA (pRS416), 10 μl single-stranded DNA (10 mg/ml) and 10 μl of freshly sonicated Sup35NM amyloid fibrils (as described above) or 1 μl of cell extract. This transformation mix was incubated for 10 min at room temperature and then 0.9 ml of PEG buffer (40% PEG 4000, 10 mM Tris-HCl pH7.5, 10 mM CaCl~2~) was added to each transformation. After 30 min at room temperature, the spheroplasts were collected by centrifugation (400 x*g*, 5 min), resuspended in 200 μl SOS media and 20 μl were added to sterile Top agar (-URA synthetic complete media with 2% agar and 1.2 M Sorbitol) being kept at 48°C, gently mixed and then poured into agar plates previously prepared using the same medium. Cells were allowed to grow for 3--4 days and then colonies were individually picked into 96 well plates containing YEPD. These were grown overnight at 30°C with agitation and then replica plated onto ¼ YEPD to check for the \[*PSI^+^*\] prion phenotype and ¼ YEPD supplemented with 3 mM GdnHCl to eliminate any false positives; 3 mM GdnHCl eliminates the \[*PSI^+^*\] prion ([@bib42]). Fragmented amyloid fibrils used in transformation experiments were simultaneously prepared for particle size distribution analysis using AFM as described below.

Atomic Force Microscopy {#s4-7}
-----------------------

20 μl of the fibril samples were diluted 1:300 and deposited on a freshly cleaved mica disc (Agar Scientific F7013). After 10 min incubation at room temperature, excess sample was removed by washing with 1 ml of 0.2 µm syringe filtered mQH~2~0 and then dried under a gentle stream of N~2~. Samples were imaged using a Bruker Multimode AFM with a Nanoscope V controller and a ScanAsyst probe (Silicone nitride tip with tip height = 2.5--8 μm, nominal tip radius = 2 nm, nominal spring constant 0.4 N/m and nominal resonant frequency 70 kHz). Images were captured at a resolution of 4.88 nm per pixel scanned. All images were processed using the Nanoscope analysis software (version 1.5, Bruker). The image baseline was flattened using third order baseline correction to remove tilt and bow, and the data was saved as processed image files and raw data files, for recognition by the fibril tracing software. A larger number of images were collected for low sonication time point samples, as long fibrils are harder to measure due to a tendency to tangle and associate in larger structures (see [Figure 2b](#fig2){ref-type="fig"}) that dissociate over extended periods of sonication. Processed image files were opened and analyzed using automated fibril tracing scripts written in Matlab ([@bib52]).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The physical dimensions of amyloid aggregates control their infective potential as prion particles\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Alexander K Buell (Reviewer \#1); Margaret Sunde (Reviewer \#2); Frederic Rousseau (Reviewer \#3).

The reviewers found the work to be of very high quality and of interest and importance. \"The study is technically extremely well performed. The data on the fibril length distributions is of exceptionally high quality and the subsequent analysis in terms of aggregation behaviour and in particular infectivity behaviour is highly convincing. \" and \"This approach developed by the authors is extremely helpful to the community as it allows to design controlled and quantifiable seeding/infectivity experiments to compare different amyloid models\"

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Marchante et al. quantify the dependence of yeast prion (sup35) infectivity on seed particle size. They find that infectivity requires seed sizes of less than 200nm. They suggest that this that cutoff results from the inability of cells to internalize large particles.

Essential points to address:

1\) There is limited correlation between the in vitro studies presented here and infectious Sup35 material. How were the \"in vitro formed prion particles\" from the \[PSI+\] extract formed? (from subsection "Characterization of Sup35NM prion particles", paragraph two)

2\) What is the infectivity of the cell extract that is analysed in parallel in [Figure 3B, i](#fig3){ref-type="fig"}.e. the control?

3\) The effect of the length of the particles on seeding efficiency does not appear to have been tested directly. What is the effect of using equal numbers of long and short particles, to directly test the efficiency of seeding with long particles?

4\) Seeding efficiency in vitro correlates with particle concentration (derived from size distribution) in such a manner that the linear fit intersects at (0,0). in vivo PSI+ induction is offset by a 200nM particle size cut-off. The authors attribute this cut-off to the inability of larger particles to enter the cell but they do not show this directly. It would be good that uptake would be directly measured, at least for two extreme conditions (e.g. 30sec vs 960s) to make this point entirely. Please at least comment on this point.

Comments from reviewers you might find helpful in your revision/further work

1\) As far as I understand, in the case of yeast prions, amyloid fibrils do not have to enter the cell from the outside, but they are rather transmitted from other to daughter cells during cell division. Also, to my knowledge, the mammalian prion protein is not intracellular. However, things are quite different with for example α-synuclein and tau aggregates, which are intracellular, and which might be able to be transmitted from cell to cell. Therefore, while the question addressed in this work is extremely interesting and relevant, the molecular system with which this has been studied might be less so. However, I see the point of course that this is in some ways the ideal system to test these kinds of things, but only because of the possibility to have a simple readout for infection, not because the question is particularly relevant in this system. This aspect should be commented on by the authors.

2\) Another point is the question whether the increased infectivity of short fibrils is simply due to enhanced diffusion. This has been brought forward as one of the explanations why small aggregate species (oligomers) are more toxic to cells -- maybe simply because they are more mobile. It would be great if the authors could comment on that, and maybe even plot the fibrillar diffusion coefficients as a function of length (see work by de la Torre for the diffusion coefficients of rods), to demonstrate that there is no dramatic cut off in diffusion coefficient at 200 nm length. This would give additional support for their hypothesis. Looking into diffusion is important in this context also because what might really matter for the transmission of yeast prions in vivo, is how they are diffusing around the cell and into the daughter cells.

3\) I am not requesting this as additional experiments (maybe a future study?), but is it possible to check how likely it is for cells to transmit prions to daughter cells, as a function of what length distribution they have been infected with?

4\) In amyloid systems (e.g. asyn) for which cell-cell transmission across the membrane could be quite relevant, it appears more and more likely, that it is not fragmentation, but surface catalysis (secondary nucleation) that is responsible for fibril amplification (see e.g. Buell et al., 2014). How does this influence the conclusions of this manuscript? In particular this might lead to the strategy that the authors suggest (make fibrils longer to stop transmission) not working, as longer fibrils can still act as a sites for the formation of secondary nuclei/toxic oligomers, and by making them longer, one produces more surface for that. This should be commented on as well.

5\) The size of the infectious Sup35 particles from the cell extract should be determined using sucrose density gradients. While it might be difficult to achieve, could the anti-Sup35 antibody be used to purify the material so that it could be imaged by AFM?

6\) The authors have developed methods that should allow them to test their hypothesis with purified preparations from sucrose density gradients that contain only particles of below or above 200 nm. This should be included in the study in order to support their major conclusions and to provide a biological correlate to the in vitro studies.

7\) There is evidence that the activity of Hsp104 and other co-chaperones is responsible for fragmentation of Sup35 particles in vivo. Is Hsp104 active on these in vitro preparations? It would be interesting to determine whether activity of Hsp104 results in a population of fibrils shorter than \~200 nm.

10.7554/eLife.27109.016

Author response

*Essential points to address:*

*1) There is limited correlation between the* in vitro *studies presented here and infectious Sup35 material. How were the \"*in vitro *formed prion particles\" from the \[PSI+\] extract formed? (from subsection "Characterization of Sup35NM prion particles", paragraph two)*

The sentence the referees refer to contains a typographical error, where it reads 'in vitro' it should read 'in vivo'. We thank the referees for pointing out this mistake and we have corrected the text accordingly. We agree with the reviewers that the link between our in vitro generated prion particles and in vivo Sup35 prions seems limited and we apologise for not making this link clearer in our manuscript. Our study was designed to isolate the effect of physical shape and size of the amyloid particles on prion transfection efficiency, and as we show in our paper, we were only able to probe these effects effectively using the synthetic yeast prions as a tractable biophysical tool. In this case, our conclusions are also entirely consistent with size-dependent prion propagation of the prion particles seen in vivo(Derdowski et al., 2010). To further address this point, we have also added new experimental data showing the transfection efficiency of in vivo formed prion particles in the form of a \[*PSI*+\] cell-free extract (subsection "Characterization of Sup35NM prion particles", [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), added information on the preparation of the cell-free extract in the Material and Methods section and added further clarifications on our approach in isolate the effect of physical shape and size of the amyloid particles using pure in vitroderived material compared to in vivoformed particles in cell-free extracts.

*2) What is the infectivity of the cell extract that is analysed in parallel in [Figure 3B, i](#fig3){ref-type="fig"}.e. the control?*

We have now added new experimental data on the transfection efficiency of the \[*PSI+*\] cell-free extract. ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). As stated in \#1 above, we agree with the reviewers that the in vivo-formed prion particles in the cell-free extract and the in vitro generated synthetic prion particles are unlikely to be identical. Here, the Sup35 concentration in the cell-free extract varies depending on the specific expression levels at the point of sample preparation and cell-free extracts will also contain chaperones and other yeast prions that may interfere with the interpretation of the transfection results. Hence, any transfection efficiency difference seen with the cell-free extract cannot be directly attributed to differences in size, shape and suprastrucutre of the amyloid particles in the same way as our synthetic and pure in vitro-generated amyloid samples. We have added this information to the Results section of our manuscript (subsection "Characterization of Sup35NM prion particles").

*3) The effect of the length of the particles on seeding efficiency does not appear to have been tested directly. What is the effect of using equal numbers of long and short particles, to directly test the efficiency of seeding with long particles?*

The reviewers suggest an important additional experiment that we have now carried out in order to directly test the predictions of our model for seeding efficiency (subsection "Influence of fibril particle concentration and size on prion transfection efficiency", yellow data points in [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, together with recalculated particles concentrations to reflect the final particles concentrations in [Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). We have also included the results of a new experiment to test the predictions for transfection efficiency ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}) in the revised manuscript. In short, our new experimental data show that equal number of particles in fibrils samples with different length distributions indeed confer the same seeding efficiency as predicted. Furthermore, our new transfection experiments also show that equal number of active particles for transfection in fibrils samples with different length distributions do confer the same transfection efficiency as predicted by our particle number and activity, based on our size cut off model. We believe these results significantly strengthen our conclusions and we thank again the referees for this very constructive suggestion.

*4) Seeding efficiency* in vitro *correlates with particle concentration (derived from size distribution) in such a manner that the linear fit intersects at (0,0).* in vivo *PSI+ induction is offset by a 200nM particle size cut-off. The authors attribute this cut-off to the inability of larger particles to enter the cell but they do not show this directly. It would be good that uptake would be directly measured, at least for two extreme conditions (e.g. 30sec vs 960s) to make this point entirely. Please at least comment on this point.*

We very much agree with the reviewer's comments on this point. In fact, direct observation of a prion particle entering a cell is something that we have tried very hard to do. For example, we have created a Sup35NM variant containing one single cysteine at the Cterminus and labelled it with FITC. We then showed that the labelled fibrils did assemble into amyloid fibrils either on its own or when mixed with wild type Sup35NM. Subsequently, we performed transfection experiments and attempted to detect the fluorescently labelled particles using confocal fluorescence microscopy. Overall, we found that 1) the absolute number of cells taking up prion particles is very low compared to the total original number of cells, 2) the nascently-transfected yeast sphaeroplasts are not stable and physically challenging to handle for confocal microscopy, 3) there is a large dilution factor when single particles enter the cell volume, and 4) the resolution of fluorescence microscopy is not high enough to distinguish the exact localisation of fluorescence signals from single particles. To our knowledge, no study to date has directly detected single amyloid particle uptake in yeast cells. However, this is of course something we are very much interested in continuing to pursue.

Consequently, we have modified the Discussion section to comment on the limitations of our indirect approach without the direct observation of the transfecting particles (paragraph six). In addition, our new data that show transfection efficiency of samples for the two extreme conditions (after 15 s and 960 s of sonication) adjusted to equal particle concentration matched predictions based on our size cut off model, taking into account the predicted activity of the samples at different length (subsection "Influence of fibril particle concentration and size on prion transfection efficiency", [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). We believe that these confirmed predictions considerably strengthen our model.

*Comments from reviewers you might find helpful in your revision/further work*

*1) As far as I understand, in the case of yeast prions, amyloid fibrils do not have to enter the cell from the outside, but they are rather transmitted from other to daughter cells during cell division. Also, to my knowledge, the mammalian prion protein is not intracellular. However, things are quite different with for example α-synuclein and tau aggregates, which are intracellular, and which might be able to be transmitted from cell to cell. Therefore, while the question addressed in this work is extremely interesting and relevant, the molecular system with which this has been studied might be less so. However, I see the point of course that this is in some ways the ideal system to test these kinds of things, but only because of the possibility to have a simple readout for infection, not because the question is particularly relevant in this system. This aspect should be commented on by the authors.*

The reviewer is absolutely correct in that we took the advantage of the well-defined readout our system offered to investigate the effect of physical properties on prion infectivity, with all the benefits and caveats purified biophysical experiments offer. Our results are nevertheless consistent with intracellular prion propagation in yeast as a 'size-based' process (Derdowski et al., 2010). We agree with the reviewers that for amyloid systems such as α-synuclein and tau aggregates, intracellular factors as well as the size cut-off we have seen in our study will play important roles. Consequently, we have added discussions on the intracellular and other factors that could further contribute to size and shape effects of prion transmission (Discussion paragraph six).

*2) Another point is the question whether the increased infectivity of short fibrils is simply due to enhanced diffusion. This has been brought forward as one of the explanations why small aggregate species (oligomers) are more toxic to cells -- maybe simply because they are more mobile. It would be great if the authors could comment on that, and maybe even plot the fibrillar diffusion coefficients as a function of length (see work by de la Torre for the diffusion coefficients of rods), to demonstrate that there is no dramatic cut off in diffusion coefficient at 200 nm length. This would give additional support for their hypothesis. Looking into diffusion is important in this context also because what might really matter for the transmission of yeast prions* in vivo*, is how they are diffusing around the cell and into the daughter cells.*

We agree with the reviewers that diffusion will be an additional factor. Using the model and the parameters reported by de la Torre and co-workers and the fact that translational diffusion scales with 1/length in this model, diffusion is likely to be a factor for particles smaller than \~50 nm. We have modified the Discussion (paragraph five and Ortega and de la Torre, 2003) to take into account this consideration.

*3) I am not requesting this as additional experiments (maybe a future study?), but is it possible to check how likely it is for cells to transmit prions to daughter cells, as a function of what length distribution they have been infected with?*

This would be extremely challenging to do. As discussed above, we have tried to detect single amyloid particle uptake in yeast cells using labelled Sup35NM without success for various technical reasons. Derdowski et al., 2010) have certainly shown using Sup35-GFP fusions that there is a molecular mass threshold that limits transmission of \[*PSI*+\] prion aggregates, i.e. propagons, during cell division although length distribution was not considered by these authors. In addition, any in vitro-generated prion particle that enters the cell will undoubtedly undergo change in length distribution and will associate with various endogenous proteins that may modulate transmissibility. Overall, we do agree that direct dynamic detection of prion particle length/size distributions in the cell would be extremely interesting and we are very much interested in continuing to pursue this avenue of research.

*4) In amyloid systems (e.g. asyn) for which cell-cell transmission across the membrane could be quite relevant, it appears more and more likely, that it is not fragmentation, but surface catalysis (secondary nucleation) that is responsible for fibril amplification (see e.g. Buell et al., 2014). How does this influence the conclusions of this manuscript? In particular this might lead to the strategy that the authors suggest (make fibrils longer to stop transmission) not working, as longer fibrils can still act as a sites for the formation of secondary nuclei/toxic oligomers, and by making them longer, one produces more surface for that. This should be commented on as well.*

We agree with the referee that the same active surfaces that promote secondary nucleation may also affect their infective potential, e.g. by altering their fibril-fibril interactions or interactions with other cellular/membrane surfaces. We have modified the Discussion to take these possibilities into account (paragraph five). We have also added that promoting the formation of large inert aggregates of transmissible particles may be a possible therapeutic strategy to reduce the infective potential of the particles (Results section paragraph one). This approach is consistent with both reducing secondary nucleation and reducing their infective activities.

*5) The size of the infectious Sup35 particles from the cell extract should be determined using sucrose density gradients. While it might be difficult to achieve, could the anti-Sup35 antibody be used to purify the material so that it could be imaged by AFM?*

We have indeed tried to image the sucrose density gradients fractionated prion particles, both in vivo and in vitro in origin, using AFM. However, as the reviewers also eluded to in their comment, we found that the high concentration of sucrose used in the gradients unfortunately makes it technically not feasible to image such samples as the sucrose heavily coats the particles and the surface substrate.

*6) The authors have developed methods that should allow them to test their hypothesis with purified preparations from sucrose density gradients that contain only particles of below or above 200 nm. This should be included in the study in order to support their major conclusions and to provide a biological correlate to the* in vitro *studies.*

We agree with the reviewer that the approach we developed in this manuscript open up a range of possible avenues of experiments to test the infective potential of a variety of in vitroand in vivopreparations. As mentioned above, the Sup35 concentration in the cell-free extract varies depending on the specific expression levels in the cell at the time of sample preparation and cell-free extracts may also contain chaperones and other yeast prions that will interfere with the interpretation of the transfection results. In addition, the absolute size of the particles in cell-free extracts cannot be determined by nanoscale imaging as mentioned above. Thus, the effect of size, shape and suprastructure cannot be isolated for a complex mixture such as sucrose gradient fractionated cell-free extracts. Nevertheless, this is an area that we are currently actively investigating.

*7) There is evidence that the activity of Hsp104 and other co-chaperones is responsible for fragmentation of Sup35 particles* in vivo*. Is Hsp104 active on these* in vitro *preparations? It would be interesting to determine whether activity of Hsp104 results in a population of fibrils shorter than \~200 nm.*

We agree with the referees that the molecular mechanism of chaperone-catalysed fibril fragmentation reactions is a very interesting as well as important question to address. While not directly related to this manuscript, this is also something we are currently actively investigating.
